	1st cohort (enrolled 1994–1998)					2nd cohort (enrolled 2004–2008)
	yr 0	yr 1	yr 2	yr 3	yr 4	yr 0	yr 1	yr 2	yr 3	yr 4

Immunosuppressive therapy (%)	68	73	75	74	72	73	80	82	79	80
Antimalarials (%)	42	42	43	42	40	37	46	54	53	54
Azathioprine (%)	23	27	26	27	27	24	24	25	23	23
Mycophenolate mofetil (%)	–	–	–	–	–	12	15	13	15	16
Combination of immunosuppressive drugs (%)	10	9	9	9	11	13	17	23	24	25
GC >7.5mg/d (%)	25	21	14	14	15	26	15	13	10	9
GC ≤7.5mg/d (%)	33	44	53	58	54	51	57	62	64	61
Pain therapy (NSAIDs, analgesics, opioids) (%)	30	28	27	31	24	22	27	33	36	35
Disease activity (%) low (0–3) vs. moderate or high (4–10)
0–3	65	77	72	72	74	72	76	79	85	88
4–10	35	23	28	28	26	28	24	21	15	13
Global Health (%), very good/good vs. moderate/poor
0–2^*	28	33	37	35	35	33	32	34	35	35
3–10	72	67	63	65	65	67	68	66	65	65
Pain (%) low (0–3), vs. moderate or high (4–10)
0–3	62	67	66	61	61	54	69	64	62	60
4–10	38	33	34	39	38	46	31	36	38	41

↵* Global Health was collected until 1999 as 5-item qualitative scale, since 2000 as NRS 0–10. Best concordance was found for qualitative categories “very good” and “good” with NRS 0–2.